Silexion Therapeutics Corp (NASDAQ:SLXN) Shares Shorted: Short Interest Up 1,964.4% in September

Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 4,925,958 shares, a growth of 1,964.4% from the September 15th total of 238,617 shares. Approximately 89.3% of the company’s shares are short sold. Based on an average daily volume of 40,442,760 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. Maxim Group downgraded Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Get Silexion Therapeutics alerts:

View Our Latest Stock Analysis on Silexion Therapeutics

Silexion Therapeutics Price Performance

NASDAQ:SLXN traded down $0.02 during mid-day trading on Friday, hitting $0.21. 790,060 shares of the company’s stock were exchanged, compared to its average volume of 3,474,559. Silexion Therapeutics has a one year low of $0.21 and a one year high of $40.70. The business has a fifty day moving average price of $0.54 and a 200 day moving average price of $3.88. The company has a market cap of $1.19 million, a PE ratio of -0.01 and a beta of -0.29.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last announced its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03. On average, equities analysts forecast that Silexion Therapeutics will post -4.70 EPS for the current fiscal year.

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat.

Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment.

The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs.

Further Reading

• Five stocks we like better than Silexion Therapeutics
• Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
• Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
• Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
• Arista Networks Plugs Into All-Time Highs

Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.